Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9993430 Tablet formulation comprising semaglutide and a delivery agent

Patent 9993430 was granted and assigned to Novo Nordisk on June, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Novo Nordisk

Current Assignee

Novo Nordisk

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

9993430

Date of Patent

June 12, 2018

Patent Application Number

14409021

Date Filed

June 19, 2013

Patent Citations Received

‌

US Patent 11833248 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

‌

US Patent 11759503 Compositions of GLP-1 peptides and preparation thereof

‌

US Patent 11759502 Compositions of GLP-1 peptides and preparation thereof

‌

US Patent 11759501 Compositions of GLP-1 peptides and preparation thereof

Patent Primary Examiner

‌

Kevin S Orwig

Patent abstract

The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9993430 Tablet formulation comprising semaglutide and a delivery agent

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API